← All trials
NCT05610085
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2023
- Primary completion
- Jul 1, 2026
- Completion date
- Dec 31, 2026
- First posted
- Nov 9, 2022
- Last posted
- Nov 9, 2022
- Enrollment
- 133
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, San DiegoLead sponsor
- University of AucklandCollaborator
- University of AucklandOverall official - principal investigator
- University of California, San DiegoCollaborator
- Sharp Mary Birch Hospital for Women & Newborns, San Diego, CACollaborator
- University of AucklandCollaborator
- University of California, San DiegoOverall official - principal investigator
- University of California, San DiegoReponsible party - principal investigator
- University of MinnesotaCollaborator
- University of MinnesotaOverall official - principal investigator
- Middlemore Hospital, New ZealandCollaborator
- University of California, San DiegoSponsor investigator
- University of AucklandOfficial
- University of California, San DiegoOfficial
- University of MinnesotaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.